Katrina K Bakken Selected Research

Therapeutics

1/2021	In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.
1/2021	Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks.
12/2017	Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
5/2016	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
7/2014	Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katrina K Bakken Research Topics

Disease

11	Neoplasms (Cancer) 02/2024 - 07/2014
11	Glioblastoma (Glioblastoma Multiforme) 02/2024 - 07/2014
2	Brain Neoplasms (Brain Tumor) 01/2024 - 04/2015
1	Melanoma (Melanoma, Malignant) 01/2024
1	Neoplasm Metastasis (Metastasis) 01/2024
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021

Drug/Important Bio-Agent (IBA)

4	Temozolomide (Temodar)FDA LinkGeneric 12/2017 - 07/2014
3	Phosphotransferases (Kinase)IBA 01/2021 - 01/2016
2	Radiation-Sensitizing AgentsIBA 02/2024 - 01/2024
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2017 - 07/2014
2	veliparibIBA 05/2016 - 07/2014
2	adavosertibIBA 01/2016 - 04/2015
1	AZD1390IBA 02/2024
1	galantide (M 15)IBA 01/2024
1	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 01/2024
1	DNA (Deoxyribonucleic Acid)IBA 01/2024
1	peposertibIBA 01/2024
1	ErbB Receptors (EGF Receptor)IBA 01/2023
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	lisavanbulinIBA 12/2022
1	depatuxizumab mafodotinIBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	XL647IBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	PhosphotyrosineIBA 01/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2017
1	talazoparibIBA 12/2017
1	ponatinibIBA 11/2017
1	Biomarkers (Surrogate Marker)IBA 05/2016

Therapy/Procedure

5	Therapeutics 01/2021 - 07/2014